A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non–Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade
Badi El Osta, Jennifer W. Carlisle, Conor Steuer, Suchita Pakkala, Ticiana Leal, Madhav V. Dhodapkar, Yuan Liu, Zhengjia Chen, Taofeek K. Owonikoko, Suresh S. Ramalingam
Topics & Concepts
DocetaxelMedicineRamucirumabPembrolizumabOncologyInternal medicineLung cancerChemotherapyClinical endpointnon-small cell lung cancer (NSCLC)Phases of clinical researchCancerNivolumabProgression-free survivalImmunotherapyClinical trialA549 cellCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies